Hikma Pharmaceuticals Public annual operating expenses
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Operating Expenses Growth & History (HIK)
Hikma Pharmaceuticals Public's operating expenses was $899.0M for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $899.0M | $96.0M | +11.96% |
| 2024 | 2024-12-31 | $803.0M | −$220.0M | −21.51% |
| 2023 | 2023-12-31 | $1.02B | $67.0M | +7.01% |
| 2022 | 2022-12-31 | $956.0M | $237.0M | +32.96% |
| 2021 | 2021-12-31 | $719.0M | $97.0M | +15.59% |
| 2020 | 2020-12-31 | $622.0M | — | — |
Hikma Pharmaceuticals Public operating expenses trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's operating expenses increased from $622.0M to $899.0M, a change of $277.0M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
reported and calculated operating expenses
TickerStat uses operating expenses reported in company official filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...